Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded in type 2 diabetes and obesity. Marking the four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results